6 results
Search Results
Now showing 1 - 6 of 6
Publication Metadata only Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis(2013-05-31) Beverley Shea; Michael V. Swinden; Elizabeth Tanjong Ghogomu; Zulma Ortiz; Wanruchada Katchamart; Tamara Rader; Claire Bombardier; George A. Wells; Peter Tugwell; University of Ottawa, Canada; Academia Nacional de Medicina de Buenos Aires; Mahidol University; Institute for Work and Health Toronto; Ottawa Hospital Research Institute© 2013 The Cochrane Collaboration. Background: Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as an antimetabolite due... effects. Objectives: To identify trials of supplementation with folic acid or folinic acid during MTX therapy for rheumatoid arthritis and to assess the benefits and harms of folic acid and folinic acid (a) in reducing the mucosal, gastrointestinal (GIPublication Metadata only Predictors for remission in rheumatoid arthritis patients: A systematic review(2010-08-01) Wanruchada Katchamart; Sindhu Johnson; Hsing Ju Lucy Lin; Veerapong Phumethum; Carine Salliot; Claire Bombardier; University of Toronto; Mahidol University; University Health Network University of Toronto; Prapokklao Hospital; Universite Paris DescartesObjective. To summarize the potential predictors of remission in patients with rheumatoid arthritis (RA). Methods. We performed a systematic review of prognostic studies that identified the predictors of remission in RA patients. Studies were... to be the independent predictors of RA remission: male sex; young age; late-onset RA; short disease duration; nonsmoker; low baseline disease activity; mild functional impairment; low baseline radiographic damage; absence of rheumatoid factor and anti - citrullinatedPublication Metadata only Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis(2010-04-14) Wanruchada Katchamart; Judith Trudeau; Veerapong Phumethum; Claire Bombardier; Mahidol University; Centre hospitalier affilié universitaire Hôtel-Dieu de Lévis; Prapokklao Hospital; Institute for Work and Health Toronto© 2015 The Cochrane Collaboration. Background: Methotrexate (MTX) is among the most effective disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) with less toxicity and better tolerability. Objectives: To evaluatePublication Metadata only Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis(2014-01-01) Beverley Shea; Michael V. Swinden; Elizabeth Tanjong Ghogomu; Zulma Ortiz; Wanruchada Katchamart; Tamara Rader; Claire Bombardier; George A. Wells; Peter Tugwell; University of Ottawa, Canada; Academia Nacional de Medicina de Buenos Aires; Mahidol University; Cochrane Musculoskeletal Group; Institute for Work and Health Toronto; Ottawa Hospital Research Instituteclinical trials in which adult patients with rheumatoid arthritis (RA) were treated with MTX (dose ≤ 25 mg/week) concurrently with folate supplementation. We included only trials using low-dose folic or folinic acid (a starting dose of ≤ 7 mg weeklyPublication Metadata only Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis(2010-07-01) Wanruchada Katchamart; Josiane Bourré-Tessier; Timea Donka; Julie Drouin; Gina Rohekar; Vivian P. Bykerk; Boulos Haraoui; Sharon LeClerq; Dianne P. Mosher; Janet E. Pope; Kam Shojania; John Thomson; J. Carter Thorne; Claire Bombardier; Kenneth Blocka; Cathy Elizabeth Flanagan; Paul Davis; Wojciech Olszynski; Vandana Ahluwalia; Michel Zummer; Gilles Boire; Jamie Henderson; Barry Koehler; Philip Baer; Zareen Ahmad; Anne St-Pierre; Martin Cohen; Maysan Abu-Hakima; Majed Khraishi; Elaine Soucy; Jacob Karsh; University of Toronto; Mahidol University; Centre Hospitalier de L'Universite de Montreal; Western University; University of Calgary; Dalhousie University; St. Joseph's Health Care London; The University of British Columbia; University of Ottawa, Canada; The Arthritis Program Research Group Inc.; Toronto General Research Institute University of TorontoObjective. To develop recommendations for the use of methotrexate (MTX) in patients with rheumatoid arthritis. Methods. Canadian rheumatologists who participated in the international 3e Initiative in Rheumatology (evidence, expertise, exchangePublication Metadata only PubMed had a higher sensitivity than Ovid-MEDLINE in the search for systematic reviews(2011-07-01) Wanruchada Katchamart; Amy Faulkner; Brian Feldman; George Tomlinson; Claire Bombardier; University of Toronto; Mahidol University; University Health Network University of Toronto; Hospital for Sick Children University of Toronto; Toronto General Research Institute University of TorontoObjective: To compare the performance of Ovid-MEDLINE vs. PubMed for identifying randomized controlled trials of methotrexate (MTX) in patients with rheumatoid arthritis (RA). Study Design and Setting: We created search strategies for Ovid-MEDLINE